Diabetes and cancer are prevalent diseases whose incidence is increasing globally. Diabetic women have a moderate risk increase in ovarian cancer, suggested to be due to an interaction between these two disorders. Furthermore, patients manifesting both diseases have associated worse prognosis, reduced survival and shorter relapse-free survival. According to current recommendations, incretin drugs such as Exenatide, a synthetic analog of Exendin-4, and Liraglutide are used as therapy for the type 2 diabetes (T2D). We studied the effects of GLP-1 and Exendin-4 on migration, apoptosis and metalloproteinase production in two human ovarian cancer cells (SKOV-3 and CAOV-3). Exendin-4 inhibited migration and promoted apoptosis through caspase 3/7 activation. Exendin-4 also modulated the expression of key metalloproteinases (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2). Vascular endothelial cells, which contribute to the formation and progression of metastasis, were also analyzed. TNF-α-stimulated endothelial cells from iliac artery after Exendin-4 treatment showed reduced production of adhesion molecules (ICAM-1 and VCAM-1). Additionally, incretin treatment inhibited activation of apoptosis in TNF-α-stimulated endothelial cells. In the same experiment, MMPs (MMP-1 and MMP-9), which are relevant for tumor development, were also reduced. Our study demonstrated that incretin drugs may reduce cancer cell proliferation and dissemination potential, hence limiting the risk of metastasis in epithelial ovarian cancer.
Summary: Introduction: Cardiovascular disease is the main cause of mortality and morbidity in the industrialized world. Incretin‐mimetic compounds such as exenatide are currently used in the treatment of type 2 diabetes.Aims: We investigated the effects of incretin drugs on apoptosis, adhesion molecule expression, and concentration of extracellular matrix (ECM) metalloproteinases under inflammatory conditions within the context of atherosclerotic plaque formation of both human coronary artery endothelial cells (hCAECs) and human aortic endothelial cells (hAoECs). TNF‐α‐stimulated hCAEC and hAoEC were treated with exenatide (1 and 10 nmol/L) and GLP‐1 (10 and 100 nmol/L) then evaluated for caspase 3/7 activity and assayed for protein levels of adhesion molecules sICAM‐1, sVCAM‐1, and P‐selectin. Concentrations of matrix metalloproteinases (MMPs) MMP‐1, MMP‐2, MMP‐9, and their inhibitors—tissue inhibitor of metalloproteinases (TIMPs), TIMP‐1, TIMP‐2 were also measured to evaluate the effects on extracellular matrix turnover within an inflammatory environment. Intracellular signaling pathways were evaluated via transfection of endothelial cells with a GFP vector under the NF‐κB promoter.Results: Our experimental data suggest that GLP‐1 receptor (GLP‐1R) agonists downregulate activation of NF‐κB and adhesion molecules ICAM and VCAM, but not P‐selectin, in both endothelial cell lines. Exendin‐4 and GLP‐1 modulate the expression of MMPs and TIMPs, with statistically significant effects observed at high concentrations of both incretins. Expressive modulation may be mediated by NF‐κB as observed by activation of the vector when stimulated under inflammatory conditions.Conclusion: These findings indicate that GLP‐1 analogs have anti‐inflammatory properties in endothelial cells that may play an important role in preventing atherosclerosis.